Federal Register Notice: FDA is amending a notice of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee announced in the 3/17 Federal Register. The date of the meeting is changed to from 5/25 to 5/24. The committee will discuss the safety and efficacy of a Novo Nordisk NDA for insulin degludec and liraglutide injection for the proposed indication: adjunct to diet and exercise to improve glycemic control in treating adults with Type 2 diabetes mellitus. Contact LaToya Bonner, (301) 796-9001. To view this notice, click here.